Anti-cancer Effects of Novel Doxorubicin Prodrug PDOX in MCF-7 Breast Cancer Cells

Overview

Journal J Huazhong Univ Sci Technolog Med Sci

Specialty General Medicine

Date 2014 Aug 20

PMID 25135721

Citations 2

Authors

Jue Zhang

Liang He

Xia-Fei Geng

Raymond A Firestone

Ya-Ping Hong

Yan Li

Affiliations

Soon will be listed here.

Abstract

Ac-Phe-Lys-PABC-DOX (PDOX) is a smart doxorubicin (DOX) prodrug designed to decrease toxicities while maintaining the potent anticancer effects of DOX. This study was aimed at elucidating the effectiveness and toxicities of DOX and PDOX in patient-derived MCF-7 breast cancer cells in vitro. The MCF-7 cells were exposed to both PDOX and DOX, and cytotoxicities, cell cycle and P53/P21 signaling alterations were studied. Abundant cathepsin B was found in the MCF-7 cells, and treatment with PDOX and DOX triggered dose- and time-dependent cytotoxicity and resulted in a significant reduction in cell viability. The IC50 of PDOX and DOX was 3.91 and 0.94 μmol/L, respectively. Both PDOX and DOX caused an up-regulation of the P53/P21-related signal pathway, and PDOX significantly increased expression of P53 and caspase 3, and arrested the cell cycle at the G1/G2 phase. As compared with DOX, PDOX reduced toxicities, and it may have different action mechanisms on breast cancer cells.

Citing Articles

Synthesis, Characterization and in vitro Studies of a Cathepsin B-Cleavable Prodrug of the VEGFR Inhibitor Sunitinib.

Karnthaler-Benbakka C, Koblmuller B, Mathuber M, Holste K, Berger W, Heffeter P Chem Biodivers. 2018; 16(1):e1800520.

PMID: 30566287 PMC: 6391952. DOI: 10.1002/cbdv.201800520.

Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer.

Zhang J, Yuan J, Wang Q, Shao L, Liu S, Firestone R Oncotarget. 2018; 9(2):1957-1968.

PMID: 29416744 PMC: 5788612. DOI: 10.18632/oncotarget.23319.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Wang Q, Zhong Y, Yuan J, Shao L, Zhang J, Tang L . Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study. J Transl Med. 2013; 11:192. PMC: 3765954. DOI: 10.1186/1479-5876-11-192. View

Schmid B, Chung D, Warnecke A, Fichtner I, Kratz F . Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem. 2007; 18(3):702-16. DOI: 10.1021/bc0602735. View

Groner B, Weiss A . Targeting survivin in cancer: novel drug development approaches. BioDrugs. 2013; 28(1):27-39. PMC: 3929033. DOI: 10.1007/s40259-013-0058-x. View

Meyer H, Wilke H . Treatment strategies in gastric cancer. Dtsch Arztebl Int. 2011; 108(41):698-705. PMC: 3221435. DOI: 10.3238/arztebl.2011.0698. View

Dubowchik G, Mosure K, Knipe J, FIRESTONE R . Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett. 1999; 8(23):3347-52. DOI: 10.1016/s0960-894x(98)00610-6. View

Cagnol S, Chambard J . ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence. FEBS J. 2009; 277(1):2-21. DOI: 10.1111/j.1742-4658.2009.07366.x. View

Okumura T . Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol. 2010; 45(11):1097-102. DOI: 10.1007/s00535-010-0310-9. View

Dubowchik G, FIRESTONE R . Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett. 1999; 8(23):3341-6. DOI: 10.1016/s0960-894x(98)00609-x. View

10.

Abu Ajaj K, Graeser R, Fichtner I, Kratz F . In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother Pharmacol. 2009; 64(2):413-8. DOI: 10.1007/s00280-009-0942-8. View

11.

Raghav N, Singh M . Design, synthesis and docking studies of bischalcones based quinazoline-2(1H)-ones and quinazoline-2(1H)-thiones derivatives as novel inhibitors of cathepsin B and cathepsin H. Eur J Pharm Sci. 2014; 54:28-39. DOI: 10.1016/j.ejps.2013.12.018. View

12.

Dubowchik G, Firestone R, Padilla L, Willner D, Hofstead S, Mosure K . Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem. 2002; 13(4):855-69. DOI: 10.1021/bc025536j. View

13.

Huynh H, Chow P, Soo K . AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther. 2007; 6(9):2468-76. DOI: 10.1158/1535-7163.MCT-07-0162. View

14.

Chen Q, Fei J, Wu L, Jiang Z, Wu Y, Zheng Y . Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients. Oncol Lett. 2012; 2(4):693-699. PMC: 3406412. DOI: 10.3892/ol.2011.302. View

15.

Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B . Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta. 2011; 1824(1):68-88. PMC: 7105208. DOI: 10.1016/j.bbapap.2011.10.002. View

16.

Pritchard A, Hayward N . Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. Clin Cancer Res. 2013; 19(9):2301-9. DOI: 10.1158/1078-0432.CCR-12-0383. View

17.

Hanaki H, Yamamoto H, Sakane H, Matsumoto S, Ohdan H, Sato A . An anti-Wnt5a antibody suppresses metastasis of gastric cancer cells in vivo by inhibiting receptor-mediated endocytosis. Mol Cancer Ther. 2011; 11(2):298-307. DOI: 10.1158/1535-7163.MCT-11-0682. View

18.

Sleeman J, Steeg P . Cancer metastasis as a therapeutic target. Eur J Cancer. 2010; 46(7):1177-80. PMC: 6545591. DOI: 10.1016/j.ejca.2010.02.039. View

19.

Kratz F, Fichtner I, Graeser R . Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model. Invest New Drugs. 2011; 30(4):1743-9. DOI: 10.1007/s10637-011-9686-5. View

20.

Shao L, Liu S, Hou J, Zhang Y, Peng C, Zhong Y . Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study. Cancer. 2011; 118(11):2986-96. DOI: 10.1002/cncr.26596. View